Beta Bionics Inc(US:BBNX)2025-10-28 20:30Q3 2025 Financial Performance - Revenue reached $27.3 million in Q3 2025[38] - Gross profit margin was 55% in Q3 2025[38] - New patient starts totaled 5,334 in Q3 2025[13] - Approximately 70% of new patient starts in Q3 2025 came from multiple daily injections[14] - New patient starts reimbursed through pharmacy were in the low 30s % in Q3 2025[14] Strategic Initiatives - The company launched the Color iLet in October 2024, featuring a color screen and brighter display[17] - The company launched Libre 3 Plus Integration in November 2024, which is the first insulin pump in the U S to integrate with Abbott's Freestyle Libre 3 Plus[17] - The company released Bionic Portal Update in May 2025, allowing HCPs to access real-time clinical outcomes for their patients[18] - The company has effective formulary agreements in place with all major PBMs operating in the U S as of July 2025[21] - The company received iLet Special 510(k) Clearance in September 2025 for usability improvements and a faster cartridge change process[22] Full Year 2025 Guidance - The company projects total revenue to be greater than $96.5 million for the full year 2025[25] - The company anticipates a gross margin of 54-55% for the full year 2025[25] - The company expects new patient starts through pharmacy to be 27-29% for the full year 2025[25]